A man suffering alopecia says he is being denied a groundbreaking new drug – despite it being approved. The daily pill, called ritlecitinib or Litfulo, was green-lit for prescription on the NHS ...

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

Opinions expressed by Forbes Contributors are their own. Dr. Omer Awan is a practicing physician who covers public health. CARLSBAD, CA-NOV 30TH: Mounjaro injection pen on display at Rachel Graham ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

JAK1/2 inhibitor Olumiant (baricitinib) was the first drug to be approved for alopecia areata in Europe, getting a green light there last year. It is currently only indicated for use in adults ...

The decision comes a few months after the first drug to be approved in the UK for alopecia – Eli Lilly’s JAK1/2 inhibitor Olumiant (baricitinib) – was turned down. Olumiant was cleared by ...

Leqselvi is now FDA approved for treating severe alopecia areata. Sun Pharma added the oral drug to its pipeline via the $576 million acquisition of Concert Pharmaceuticals last year. Pfizer’s ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...

The following is a summary of “A year in review: new treatments and expanded indications in dermatology in 2024,” published in the January 2025 issue of Dermatology by McGrath et al. In 2024, ...

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart. The company said ...